Insider Trading Alert - WNR, GALE, AOS, ALXN And IBKR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Jan. 31, 2014, 83 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $72.21 to $38,045,742.50.

Highlighted Stocks Traded by Insiders:

Western Refining (WNR) - FREE Research Report

Jewell William R who is Chief Accounting Officer at Western Refining sold 10,000 shares at $40.00 on Jan. 31, 2014. Following this transaction, the Chief Accounting Officer owned 88,119 shares meaning that the stake was reduced by 10.19% with the 10,000-share transaction.

The shares most recently traded at $38.62, down $1.38, or 3.57% since the insider transaction. Historical insider transactions for Western Refining go as follows:

  • 4-Week # shares sold: 100,000
  • 12-Week # shares sold: 680,351
  • 24-Week # shares sold: 911,617

The average volume for Western Refining has been 1.7 million shares per day over the past 30 days. Western Refining has a market cap of $3.1 billion and is part of the basic materials sector and energy industry. Shares are down 7.78% year-to-date as of the close of trading on Friday.

Western Refining, Inc. operates as an independent crude oil refiner and marketer of refined products. It operates in three segments: Refining, Wholesale, and Retail. The stock currently has a dividend yield of 2.25%. The company has a P/E ratio of 8.4. Currently there are 4 analysts that rate Western Refining a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WNR - FREE

TheStreet Quant Ratings rates Western Refining as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, attractive valuation levels and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Western Refining Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Galena Biopharma (GALE) - FREE Research Report

Schwartz Mark W. who is EVP & Chief Operating Officer at Galena Biopharma sold 100,000 shares at $5.57 on Jan. 31, 2014. Following this transaction, the EVP & Chief Operating Officer owned 409,665 shares meaning that the stake was reduced by 19.62% with the 100,000-share transaction.

The shares most recently traded at $4.48, down $1.08, or 24.22% since the insider transaction.

The average volume for Galena Biopharma has been 7.6 million shares per day over the past 30 days. Galena Biopharma has a market cap of $569.3 million and is part of the health care sector and drugs industry. Shares are up 9.07% year-to-date as of the close of trading on Friday.

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care. It is developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide. Currently there are 9 analysts that rate Galena Biopharma a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GALE - FREE

TheStreet Quant Ratings rates Galena Biopharma as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share. Get the full Galena Biopharma Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

A.O. Smith Corporation (AOS) - FREE Research Report

Greubel William P who is Director at A.O. Smith Corporation sold 8,509 shares at $47.25 on Jan. 31, 2014. Following this transaction, the Director owned 0 shares meaning that the stake was reduced by 100% with the 8,509-share transaction.

The shares most recently traded at $46.70, down $0.55, or 1.18% since the insider transaction. Historical insider transactions for A.O. Smith Corporation go as follows:

  • 4-Week # shares sold: 13,410
  • 12-Week # shares sold: 13,410
  • 24-Week # shares sold: 77,742

The average volume for A.O. Smith Corporation has been 908,400 shares per day over the past 30 days. A.O. Smith Corporation has a market cap of $3.7 billion and is part of the industrial goods sector and industrial industry. Shares are down 11.36% year-to-date as of the close of trading on Friday.

A. O. Smith Corporation engages in the manufacture and sale of water heaters and boilers to the residential and commercial markets primarily in the United States, Canada, Europe, India, and China. The company operates in two segments, North America and Rest of World. The stock currently has a dividend yield of 1.26%. The company has a P/E ratio of 23.2. Currently there are 2 analysts that rate A.O. Smith Corporation a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AOS - FREE

TheStreet Quant Ratings rates A.O. Smith Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full A.O. Smith Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Alexion Pharmaceuticals (ALXN) - FREE Research Report

Bell Leonard who is Ceo at Alexion Pharmaceuticals sold 2,660 shares at $133.81 on Jan. 31, 2014. Following this transaction, the Ceo owned 975,066 shares meaning that the stake was reduced by 0.27% with the 2,660-share transaction.

Squinto Stephen P who is EVP, Chief Global Ops. Officer at Alexion Pharmaceuticals sold 1,118 shares at $133.31 on Jan. 31, 2014. Following this transaction, the EVP, Chief Global Ops. Officer owned 103,068 shares meaning that the stake was reduced by 1.07% with the 1,118-share transaction.

Sinha Vikas who is Evp & Cfo at Alexion Pharmaceuticals sold 994 shares at $133.43 on Jan. 31, 2014. Following this transaction, the Evp & Cfo owned 133,327 shares meaning that the stake was reduced by 0.74% with the 994-share transaction.

Hallal David who is EVP, Chief Commercial Officer at Alexion Pharmaceuticals sold 729 shares at $133.45 on Jan. 31, 2014. Following this transaction, the EVP, Chief Commercial Officer owned 108,949 shares meaning that the stake was reduced by 0.66% with the 729-share transaction.

The shares most recently traded at $155.69, up $22.24, or 14.29% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 12-Week # shares sold: 3,500
  • 24-Week # shares sold: 37,887

The average volume for Alexion Pharmaceuticals has been 1.1 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $31.8 billion and is part of the health care sector and drugs industry. Shares are up 21.91% year-to-date as of the close of trading on Friday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has a P/E ratio of 52.6. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Alexion Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Interactive Brokers Group (IBKR) - FREE Research Report

Galik Milan who is SVP Software Development at Interactive Brokers Group sold 1,000 shares at $21.66 on Jan. 31, 2014. Following this transaction, the SVP Software Development owned 826,517 shares meaning that the stake was reduced by 0.12% with the 1,000-share transaction.

The shares most recently traded at $20.96, down $0.70, or 3.34% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 16,000
  • 12-Week # shares sold: 53,000
  • 24-Week # shares sold: 110,000

The average volume for Interactive Brokers Group has been 599,000 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.1 billion and is part of the financial sector and financial services industry. Shares are down 12.9% year-to-date as of the close of trading on Friday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.87%. The company has a P/E ratio of 24.9. Currently there are 3 analysts that rate Interactive Brokers Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug